Piperacillin/Tazobactam in critically ill morbidly obese patients: A case series: The first One‐Centre experience with TDM

The aim of this article is to demonstrate extreme interindividual variability of piperacilin/tazobactam (PIP/TAZO) pharmacokinetics in critically ill morbidly obese patients and to emphasize the need for the practice of routine PIP/TAZO plasma concentrations measurement in order to ensure optimal ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Mieresova, M., Balazova, K., Kubele, J., Cerny, D., Halacova, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008261/
https://www.ncbi.nlm.nih.gov/pubmed/36919150
http://dx.doi.org/10.1002/ccr3.7032
Descripción
Sumario:The aim of this article is to demonstrate extreme interindividual variability of piperacilin/tazobactam (PIP/TAZO) pharmacokinetics in critically ill morbidly obese patients and to emphasize the need for the practice of routine PIP/TAZO plasma concentrations measurement in order to ensure optimal efficacy and safety of antibiotic therapy.

Ejemplares similares